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Summary 
CTLA-4 is a T  cell antigen that is structurally related to CD28 and serves as a high affinity 
ligand for the B cell antigen B7-1/2. Unlike CD28, the function of CTLA-4 is unclear, although 
reports have implicated the antigen in the costimulation of T cells. Recently, phosphatidylinositol 
3-kinase (PI 3-kinase) has been implicated in the costimulatory function of CD28 by virtue of 
its ability to bind to a pYMNM motif within the cytoplasmic tail of the antigen. In this study, 
we show that CTLA-4 can also associate with PI 3-kinase as detected by lipid kinase analysis 
and immunoblotting with anti-p85 antiserum. High pressure liquid chromatographic separation 
of deacylated lipids showed the presence of a peak corresponding to PI-3-P. Anti-CTLA-4 ligation 
of the receptor induced a significant  increase in the levels of precipitable  PI 3-kinase  activity. 
Peptide binding studies revealed that the NH2- and COOH-terminal SH2 domains of p85 bind 
the CTLA-4 cytoplasmic pYVKM motif with an affinity (IDs0:0.6  and 0.04/~M), that is similar 
to CD28.  CTLA-4 binding to PI 3-kinase provides further evidence that CTLA-4 is not an 
inert counterreceptor, but rather is coupled to an intraceUular signaling molecule with the capacity 
to regulate cell growth. 
T  ceU activation occurs in at least two steps: an antigen- 
specific  signal  generated  by  the  TCR~'/CD3  and 
CD4/CDS-p56  ~' complexes, followed by a second signal de- 
livered by an accessory cell (1-4).  CD28, a member of the 
immunoglobulin supergene family, serves as a predominant 
second signal in the activation process (1-4).  CD80 (B7-1) 
and related B7-2/B70 serve as ligands for CD28 (4-6). These 
variant forms of B7 are differentially expressed on resting and 
activated B cells and adherent cells during the activation pro- 
cess (5, 6). Certain naive T cells appear to require a second 
signal mediated by an interaction between CD28 and B7-1 
or B7-2. Consistent with this, CD28 negative transgenic mice 
exhibit profound defects in mitogenic responses (7). In addi- 
tion, suboptimal proliferation induced by antigen, anti-CD3, 
or anti-CD2 is augmented by CD28 ligation (8, 9). T cell 
nonresponsiveness or anergy can be reversed by CD28 en- 
gagement, an event of potential importance in the genera- 
tion of cytolytic responses  against tumors (10, 11). 
In terms of CD28-mediated signaling, we have demon- 
strated that CD28 binds to the intraceUular lipid kinase phos- 
phoatidylinositol 3-kinase (PI 3-kinase) by means of a pYMNM 
motif within its cytoplasmic tail (12). Others have reported 
similar findings (13, 14). Furthermore, CD28 ligation has 
been reported to generate D-3 lipids (15). PI 3-kinase is a 
heterodimer consisting of an adaptor subunit (p85) with two 
SH2 domains that is coupled to a p110 catalytic subunit (p110) 
that phosphorylates the D-3 position of the inositol ring of 
phosphatidylinositol (PI), phosphatidylinositol 4-phosphate, 
and phosphatidylinositol 4,5 bisphosphate, generating PI 3- 
P, PI 3,4-P2, and PI 3,4,5-P3 (16, 17). Reconstitution experi- 
ments using the baculovirus-expressed  p85 subunit of PI 3- 
kinase showed that CD28 bound directly to the p85 subunit, 
without the need for the associated p110 subunit (12). More- 
over, peptide binding analysis showed that the CD28 pYMNM 
motif bound to the p85 COOH-  and NH2-terminal SH2 
domains with an affinity comparable to that observed for the 
platelet  derived growth factor receptor (PDGF-IL)  and in- 
sulin receptor substrate-1 (12). Engagement of CD28 induced 
a dramatic increase in the recruitment of PI 3-kinase by the 
receptor (12, 13). CD28 may therefore use PI 3-kinase as a 
second signal  leading to IL-2 production, stabilization  of 
mRNA for various lymphokines, and/or proliferation (1-4). 
Indeed, a recent report has demonstrated that mutation of 
the pY-191 residue abrogated the induction of IL-2 by CD28 
(18). A similar motif in the PDGF-R has been found essen- 
tial to signaling by growth factor (19, 20). 
CTLA-4 is structurally related to CD28, and is encoded 
by an adjacent  gene (21). However, in contrast to CD28, 
CTLA-4 expression is restricted to activated T cells (22). Max- 
imal expression is observed 2-3 d after TCR~'/CD3 ligation. 
Its expression is regulated by CD28 and appears on a subset 
of T cells that coexpresses CD28 (22). Much debate relates 
351  J. Exp.  Med.  ￿9  The Rockefeller  University Press  ￿9 0022-1007/95/01/0351/05  $2.00 
Volume  181  January  1995  351-355 to  whether  CTLA-4  can  provide  costimulatory  function. 
Given its lack of expression on resting  cells,  the antigen  is 
not obviously involved in the costimulation of naive T cells. 
However, CTLA-4 binds to B7 with a 20-fold higher affinity 
than CD28 (23). CTLA-4 may act to provide costimulatory 
signals  on activated T cells in cooperation with CD28 (24). 
Given this uncertainty regarding the function of CTLA-4, 
an important issue concerns the nature of the mechanism by 
which CTLA-4 may generate intracellular signals, and whether 
these differ from the signals generated by CD28.  CTLA-4 
possesses  a modified version of pYMXM motif encoded as 
pYXXM (3,  12, 21).  In this study, we show that  CTLA-4 
can bind to PI 3-kinase,  and that  CTLA-4 ligation  results 
in an increase in the binding of the lipid kinase to its receptor. 
Peptide binding studies revealed that the NH2- and COOH- 
terminal SH2 domains of p85 bind the CTLA-4 cytoplasmic 
pYVKM motif with an affinity (IDs0:0.6 and 0.04 IzM) that 
is  similar  to  CD28  (IDs0:0.6  and  0.08  #M).  CTLA-4  is 
therefore likely to share in the production of intracellular  signals 
generated  by CD28. 
Materials  and Methods 
Reagents, Cells, and Antibodies.  Reagents and their sources have 
been described (12). Antibodies included anti-CD28 (L293; Becton 
Dickinson & Co., San Jose, CA), anti-CTLA-4 (11D4; IgG1, sub- 
mitted by Dr. Peter Linsley, Bristol-Myers Squibb Pharmaceutical 
Research Institute,  Seattle, WA) and 1D6; IgM, submitted by Dr. 
Pierre  Golstein,  Centre  d'Immunologie  INSERM-CNRS  de 
Marseille-Luminy, France), provided in collaboration with the Fifth 
International  Workshop  and  Conference  on Human  Leukocyte 
Differentiation  Antigens;  anti-p85  of PI3-kinase  (Transduction 
Laboratories, Lexington, KY); and rabbit anti-mouse immunoglob- 
ulin (Dako Corp.,  Carpinteria,  CA).  The T lymphoblastoid cell 
line SPP were cultured in RPM11640 containing 5% (vol/vol) fetal 
bovine serum, t-glutamine  (2 mM), penicillin (100 U/ml), strep- 
tomycin (100 mg/ml), and Hepes buffer solution (10 mM) at 37~ 
with  an  atmosphere  of 5%  COs.  T  lymphocytes  (obtained by 
E-rosetting  of Ficoll gradient-separated  mononuclear  cells) were 
stimulated with PHA (Sigma Chemical Co., St. Louis, MO) for 
24 h (10/~g/ml). 
Iramunolnecipitation  and Lipid Kinase Assays.  Cells were solubi- 
lized in NP-40 (1% vol/vol) based lysis buffer with protease and 
phosphatase inhibitors PMSF, 1 raM; sodium vanadate, I mM; and 
subjected to precipitation,  as described (12). Immune complexes 
were washed three times with the lysis buffer, three  times with 
100 mM "Iris, pH 7.5 with 0.5 M LiC1 and twice with TNE (10 
mM Tris-HCl,  pH 7.5, 150 mM NaC1, and 1 mM EGTA). The 
lipid kinase reaction was carried out on the beads using soybean 
PI liposomes and 3r  (20 #Ci). Lipids were then extracted 
and separated by TLC as described (12). 
Western Blotting.  Anti-CTLA-4 immunoprecipitates  from SPP 
cells were immunoblotted with an anti-p85 antiserum. Reactivity 
was determined by using horseradish peroxidase-conjugated  anti- 
rabbit  antibodies and the enhanced chemiluminescence detection 
reagents (ECL; Amersham Corp., Arlington  Heights,  IL), as de- 
scribed (12). 
Receptor  Cross-linking.  For cross-linking of  the CTLA-4 antigen, 
SPP cells (150 x  10~/ml) were suspended in medium at 37~  con- 
taining 2% FCS (vol/vol), and a cocktail of anti-CTLA-4 (10-15 
/xg)/rabbit  anti-mouse antibodies  (1/~g/ml).  After  1, 5, and 10 
min, the cells were pelleted, immediately washed in ice-cold RPMI 
without FCS, and lysed in lysis buffer at 4~  as described (12). 
Peptide.binding Analysis.  Phosphopeptide binding analysis was 
conducted as described (25). p85 NH2- and COOH-terminal SH2 
domains containing glutathione S-transferase (GST) fusion proteins 
were constructed,  expressed in bacteria, and purified as described 
(25).  Competition  analysis between  12SI-labeled CTLA-4  phos- 
phopeptide (PGVpYVKMPPTE) and cold peptides with GST-p85 
SH2 were carried out, as described (25). The percentage of bound 
peptide was calcuhted  and plotted against the log concentration 
of peptide to determine the molar concentration required for 50% 
displacement (IDs0) of p85-SH2 bound peptide. 
Results and Discussion 
Initially,  anti-CTLA-4 was used to precipitate antigen from 
PHA-stimulated  peripheral  T  cells  that  had been activated 
for some 24-36 h and assessed for lipid kinase activity (Fig. 
1).  Under  these  conditions,  anti-CTLA-4  was  found  to 
generate PI-P indicating the presence of lipid kinase activity 
(lane 2). The spot comigrated with a spot generated by an 
antiserum to PI 3-kinase (lane 3). Similar analysis  was con- 
ducted using the human T cell line SPP that expresses CTLA-4 
(26).  This  cell line  offered the  advantage  that  the  CTLA- 
4-associated PI 3-kinase could be studied in the absence of 
CD28 expression.  SPP cells were lysed in an NP-40-based 
lysis buffer and subjected to immunoprecipitation  and lipid 
kinase analysis.  As shown in Fig.  1,  anti-CTLA-4  precipi- 
tated detectable amounts  of PI-3 kinase  activity from SPP 
cells, as detected by TLC (lane 5). Again, precipitates using 
antiserum  against  the p85 subunit  of PI-3 kinase served as 
a positive control (lane 6). In the case of both PBL and SPP 
cells,  rabbit  anti-mouse  served as negative control (lanes  I 
and 4). Precipitation using antibodies to CD2 and CD5 also 
failed  to precipitate  activity (data not  shown). 
To assess whether CTLA-4 ligation could induce a change 
in receptor-associated  PI 3-kinase activity, receptors were cross- 
linked with  anti-CTLA-4  mAb for various times  at 37~ 
and assayed for lipid kinase activity. As seen in Fig. 2, anti- 
CTLA-4 ligation on intact cells resulted in a marked increase 
Figure  1.  CTLA-4  associates  with PI 3-kinase  in peripheral T cells  and 
in the T cell line SPP. Activated  blood T cells (lanes I-3) and SPP cells 
(lanes 4-6) were solubitized  in NP-40  (1% vol/vol)  followed  by immuno- 
precipitation using  5/zg of  anti-CTLA-4 Ab and 1/zg of  rabbit anti-mouse 
for 1 h, as described  (12). Precipitates  were assessed  for an ability to label 
exogenously added liposomes which were separated by TLC. Rabbit 
anti-mouse (lanes 1 and 4); anti-CTLA-4 (lanes 2 and 5); and anti-p85 
of PI 3-kinase (lanes 3 and 6). 
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of receptor associated  PI 3-kinase activity. SPP cells  were exposed to a cocktail 
of 5/~g of anti-CTLA-4 and 1/~g of rabbit anti-mouse for 1, 5, and 10 
min before solubilization  in NP-40 lysis buffer, immunoprecipitation, and 
labeling in a lipid kinase assay. Time 0 represents an anti-CTLA-4 precipi- 
tate taken from cells before cross-linking. (Lane I) 0 rain; (lane 2) 1 min; 
(lane 3) 5 rain;  (lane 4) 10 min;  (lane 5) anti-p85 control. 
in the level of PI 3-kinase activity precipitated by the anti- 
CTLA-4 antibody. By comparison with unligated cells (t = 
0 rain; lane 1), cross-linking resulted in a dramatic increase 
in activity as early as 1 min, peaking at 5 min, and began 
to undergo a reduction by 10 min (lanes 2-4).  This kinetic 
is similar to that previously described for anti-CD28 (12). 
An anti-p85 precipitate served as a positive control (lane 5). 
To confirm that the CTLA-4-precipitated lipid kinase gener- 
ated PI 3-P, HPLC analysis was conducted on the eluted PI-P 
spots. As seen in Fig. 3 A, HPLC separation showed that 
the peak corresponds to PI 3-P. To further establish the pres- 
ence of  PI 3-kinase, anti-CTLA-4 precipitates were subjected 
to immunoblotting with an antibody to the p85 subunit of 
PI 3-kinase (Fig. 3 B). Both approaches confirmed the pres- 
ence of PI 3-kinase associated with CTLA-4 in T  cells. 
CTLA-4 possess a pYVKM motif within its cytoplasmic 
tail (3, 21), a motif that should be suitable for binding to 
PI 3-kinase (27). We previously showed that the two SH2 
domains of  p85 bound to a related motif  (pYMNM) on CD28, 
with an avidity that is comparable to the PDGF-R (12). To 
establish whether the CTLA-4 cytoplasmic pYVKM motif 
could bind to one or both p85 SH2 domains, peptide binding 
analysis was  conducted.  In  the  assay, inhibition  of t2sI- 
radiolabeled phosphopeptide binding was dependent on the 
concentration of the unlabeled phosphopeptide.  No inhibi- 
tion was observed at the lowest peptide concentration (1-100 
nM for the NH2-terminal SH2 domain and 1-10 nM for the 
COOH-terminal peptide),  while 100% inhibition was ob- 
served at the highest concentrations  (>10/~M for the NH2- 
terminal SH2 domain and >1 #M for the COOH-terminal 
SH2 domain). As seen in Fig. 4, the peptide encoding the 
CTLA-4 peptide sequence (PGVpYVKMPPTE) was found 
to bind with high affinity to both the NH2-terminal  and 
COOH-terminal p85 SH2 domains. The nonphosphorylated 
version of the same peptide failed to bind. Half-maximal in- 
hibition  (IDs0) was  observed  at  0.6  /~M  for  the  NH2- 
terminal domain, and 0.04/~M for the COOH-terminal do- 
main (left  and right panels, respectively).  In addition, a number 
of other interesting points were observed. First, the affinity 
of the CTLA-4 pYVKM motif for the NH2- and COOH- 
terminal domains was virtually the same as observed for the 
CD28 pYMNM motif. In both cases, the IDs0 for binding 
to the NH2-terminal  domains is 0.6/xM, whereas the IDs0 
for CTLA-4 and CD28 binding to the COOH-terminal do- 
main is 0.04/~M and 0.08/~M, respectively. In both cases, 
the COOH-terminal SH2  domain bound with  '~10-fold 
higher  affinity  than  the  NH2-terminal  domain.  Lastly, 
similar affinities were observed for motifs within the PDGF- 
R (pY740 and pY751), middle T antigen pY315, and the CSF- 
1R pY721 sites. Therefore, the binding motif  within CTLA-4 
bound to p85 with an avidity comparable to those previously 
observed for other functionally relevant interactions. 
Considerable debate exists regarding the function of CTLA-4 
in T cell stimulation.  Its absence on naive T cells precludes 
a role for this antigen in the costimulation of  unprimed cells. 
Figure  3.  High pressure liquid chromato- 
graphic and immunoblotting analysis  of CTLA- 
4-associated PI 3-kinase. (A) PI-P spots were 
extracted from TIC, deacylated, and subjected 
to HPI.C analysis (12). (~p) PI-P generated in 
anti-CTLA-4 precipitate consists  of PI  3-P. 
Control (rabbit anti-mouse) (A), anti-CTLA-4 
(0). (Bottom) p85 served as a positive control 
for PI 3-P (A), while [3H]PI-4 P served as an 
internal standard for PI  4-P  ([3).  Anti-p85 
immunoprecipitate (A) and PI 4-P standard 
([3).  (B) Anti-p85 immunoblotting of anti- 
CTLA-4 precipitates. SPP cells were subjected 
to  anti-CTLA-4  immunoprecipitation  and 
immunoblotting  with  anti-p85  sera,  as  de- 
scribed 02). 
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Figure  4.  Binding  of the CTLA~ phosphopeptide  (PGVpYVKMPPTE) 
to the SH2 domains of the p85 subunit of PI 3-kinase. Binding assays 
were carried out with the 10-amino acid tyrosine~  CTLA-4 
peptide (pY191) bound to p85 N-SH2 (left) and p85 C-SH2 (right). The 
competition analysis between 12SI-labeled  CTLA-4 phosphopeptide (PGV- 
pYVKMPPTE) and cold peptides with GST-p85 SH2 was carried out, as 
described (25). The x axis represents log of peptide concentration used 
(M) and the y axis the percent bound peptide. Curves generated using 
the phosphopeptide  (I, @) and the nonphosphorylated peptides ([3, O) 
are shown. IDs0 values are also shown, in comparison to similar values 
generated for other phosphopeptides containing binding motifs. 
Instead, it is expressed on T cells some 24-48 h after TCR~/ 
CD3  ligation  (22).  CTLA-4 has  been proposed to be an- 
tagonistic to the function of CD28, whereas more recent evi- 
dence has indicated that CTLA-4 may act to provide costimula- 
tory signals  in cooperation with  CD28  on primed  CD4 § 
T cells (24). As outlined, our study provides a molecular basis 
for CTLA-4 function by demonstrating  that  CTLA-4 can 
associate with PI 3-kinase in a manner similar to CD28. Li- 
gation of CTLA-4 also resulted in an increase  in receptor- 
associated lipid kinase activity, and the SH2 domains of the 
p85 subunit ofPI 3-kinase were found to bind to the pYVKM 
motif with an affinity similar to the pYMNM motif within 
CD28.  This  common  property  indicates  that  CD28  and 
CTLA-4  share  a signaling  function  in T  cells.  In the case 
of CD28, Pages et al. (18) have recently demonstrated that 
mutation of pY within the pYMXM motif abrogated CD28 
induced IL-2 production. The importance of the interaction 
is also underlined by the fact that other signaling receptors 
for PDGF, epidermal growth factor, insulin, and CSF-1 bind 
to this kinase, and in the case of the PDGF-R,  the interac- 
tion has been shown to be essential  to signaling by growth 
factor (19,  20).  Past difficulties in demonstrating  CTLA-4 
costimulation may therefore be related to its low level of ex- 
pression on T  cells.  As pointed out by Linsley et al.  (24), 
even  at  maximal  levels  of expression,  CTLA-4  expression 
reaches  only some 3%  of that  found for CD28. 
Identification of the CTLA-4 complex formation with PI 
3-kinase also may assist in the interpretation of other results 
in the literature. Although significantly immunocompromised, 
CD28-negative transgenic mice are not completely lacking 
in an ability to respond to foreign antigen (9). For example, 
these mice can mount a response to infection with cytomeg- 
alovirus.  CTLA-4 possesses the appropriate interaction with 
PI 3-kinase that should enable it to substitute for and/or syn- 
ergize with  CD28 in certain  responses. 
As in the case of CD28, attempts to demonstrate tyrosine 
phosphorylation of CTLA-4 has resulted in equivocal results 
(data not shown). This may reflect the low degree of stoi- 
chiometry of phosphorylation and the relative insensitivity 
of labeling methods. In another study, chimeras carrying the 
cytoplasmic tails of CTLA-4 failed to bind PI 3-kinase (28). 
Although  the basis for the difference in results is unclear, 
it is possible that chimeric constructions may alter the binding 
characteristics of the cytoplasmic tail of CTLA-4. Our study 
used the wild-type native CTLA-4 molecule to examine the 
presence of associated PI 3-kinase (Figs. 1-4). As with CD28, 
associated PI 3-kinase may regulate a number of intracellular 
events.  PI  3,  4,  5-P3 has  been reported  to  regulate  the  ~- 
isoform of protein  kinase C  and  pp70  ~k (29,  30).  The  PI 
3-kinase homologue  Vps34 and related  Tor2 in yeast regu- 
lates  protein  sorting/transport  and  cell cycle progression, 
respectively  (31).  The  loss  of PI-3  kinase  binding  to  the 
PDGF-R has also been correlated with a disruption of receptor 
endocytosis (32). The manner by which CTLA-4-associated 
PI 3-kinase is coupled to these functions remains to be de- 
termined. 
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